New therapeutic approaches for familial amyloidotic polyneuropathy (FAP)

References

• Andrade C (1952). A peculiar form of peripheral neuropathy: Familial generalized amyloidosis with special involvement of the peripheral nerves. Brain 75, 408–427
   PubMed Web of Science ®Google Scholar
• Araki S (1984). Type I familial amyloidotic polyneuropathy (Japanese type). Brain Dev 6, 128–133
   PubMed Web of Science ®Google Scholar
• Benson MD (1989). Familial amyloidotic polyneuropathy. Trends Ncurosci 12, 88–92
   PubMed Web of Science ®Google Scholar
• Benson MD and Uemichi T (1996). Transthyretin amyloidosis. Amyloid: Int J Exp Clin Invest 3, 44–56
   Web of Science ®Google Scholar
• Ando Y, Araki S and Ando M (1993). Transthyretin related amyloidosis. Intern Med 32, 920–922
   PubMed Web of Science ®Google Scholar
• Ando Y and Suhr O (1998). Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP). Amyloid: Int J Exp Clin Invest 5, 288–300
   PubMed Web of Science ®Google Scholar
• Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, Wallin BG, Seymour A, Richardson S, Hawkins PN and Pepys MB (1993). Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341, 113–116
   Web of Science ®Google Scholar
• Ericzon BG, Holmgren G, Lundgren E and Suhr OB (1999). New structural information and update on liver transplantation in transthyretin-associated amyloidosis. Report from the 4th International Symposium on Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders & the 3rd International Workshop on Liver Transplantation in Familial Amyloid Polyneuropathy, Umea Sweden, June 1999. Amyloid: Int J Exp Clin Invest 7, 145–147
   Google Scholar
• Skinner M, Lewis WD, Jones LA, Kasirsky J, Kane K, Ju ST, Jenkins R, Falk RH, Simms RW and Cohen AS (1994). Liver transplantation as a treatment for familial amyloidotic polyneuropathy. Ann Intern Med 120, 133–134
   PubMed Web of Science ®Google Scholar
• Takei Y, Ikeda S, Hashikura Y, Ikegami T and Kawasaki S (1999). Partial-liver transplantation to treat familial amyloid polyneuropathy: Follow-up of 11 patients. Ann Intern Med 131, 592–595
   PubMed Web of Science ®Google Scholar
• Ando Y, Tanaka Y, Ando F., Yamashita T, Nishida Y, Tashima K, Suga M, Uchino M and Ando M (1995). Effect of liver transplantation on autonomic dysfunction in familial amyloidotic polyneuropathy type I. Lancet 345, 195–196
   PubMed Web of Science ®Google Scholar
• Suhr O, Danielsson A, Rydh A, Nyhlin N, Hietala SO and Steen L (1996). Impact of gastrointestinal dysfunction on survival after liver transplantation for familial amyloidotic polyneuropathy. Dig Dis Sci 41, 1909–1914
   PubMed Web of Science ®Google Scholar
• Lendoire J, Trigo P, Aziz H, Cueto G, Ando Y, Tashima K, Ohlsson PI, Cederquist K, Holmgren G and Suhr OB (1999). Liver transplantation in transthyretin familial amyloid polyneuropathy: First report from Argentina. Amyloid: Int J Exp Clin Invest 6, 297–300
   PubMed Web of Science ®Google Scholar
• Ando Y, Terazaki H, Haraoka K, Tajiri T, Nakamura M. Obayashi K, Misumi S, Shoji S, Hata K, Nakagawa K, Ishizaki T, Uemoto S, Inomata Y, Tanaka K and Okabe H (2002). Presence of autoantibody against ATTRVal30Met alter sequential liver transplantation. Transplantation 73, 674–675
   PubMed Web of Science ®Google Scholar
• Ando E, Ando Y and Haraoka K (2001). Ocular amyloid imvolvement after liver transplantation for polyneuropathy. Ann Intern Med 135, 931–932
   PubMed Web of Science ®Google Scholar
• Sales-Luis ML, Galvao M, Carvalho M, Sousa G, Alves MM and Serrao R (1991). Treatment of familial amyloidotic polyneuropathy (Portuguese type) by plasma exchange. Muscle Nerve 14, 377–378
   PubMed Web of Science ®Google Scholar
• Continho P, Macedo E, Estacio A, Saraiva A, Costa PP and Saraiva MJM (1988). Periodic plasma exchanges in treatment of familial amyloid polyneuropathy: Preliminary results. In Isobe T, Araki S, Uchino F, Kito S and Tsubura E (eds). Amyloid and Amyloidosis, pp 845-849. (New York: Plenum Press)
   Google Scholar
• Ikegawa S, Tanase S, Morino Y, Yi S, Ando Y, Miyazaki A and Araki S (1988). Evaluation of serum variant prealbumin levels, and its behavior after plasma exchange for familial amyloidotic polyneuropathy (type 1). In Isobe T, Araki S, Uchino F, Kito S and Tsubura E (eds). Amyloid and Amyloidosis, pp 839-844. (New York: Plenum Press)
   Google Scholar
• Regnault V, Costa PM, Teixeira A, Rivat C, Stoltz JF, Saraiva MJ and Costa PP (1992). Specific removal of transthyretin from plasma of patients with familial amyloidotic polyneuropathy: Optimization of an immunoadsorption procedure. Int J Artif Organs 15, 249–255
   PubMed Web of Science ®Google Scholar
• Costa PMP and Costa PP (1998). The future of selective apheresis in FAP. Amyloid: Int J Exp Clin Invest 5, 143–144
   PubMed Web of Science ®Google Scholar
• Tokuda T, Kondo T, Hanaoka N, Takei Y, Kametani F, Yamada Y. Tamura Y, Yoshida M, Yamawaki N and Ikeda S (1998). A selective transthyretin-adsorption column for the treatment of patients with familial amyloid polyneuropathy. Amyloid: Int J Exp Clin Invest 5, 111–116
   PubMed Web of Science ®Google Scholar
• Jouquan J, Pennec Y, Mottier D, Boles JM, Morin JF, Youinou P and Garre M (1983). Retinol carrier protein, prealbumin and transferrin. Influence of age and sex on the serum concentration of proteins with a short half-life. Presse Med 12, 1877
   PubMed Web of Science ®Google Scholar
• Dickson PW, Howlett GJ and Schreiber G (1982). Metabolism of prealbumin in rats and changes induced by acute inflammation. Eur J Biochem 129, 289–293
   PubMedGoogle Scholar
• Ando Y, Tanaka Y, Nakazato M, Ericzon BG, Yamashita T, Tashima K, Sakashita N, Suga M, Uchino M and Ando M (1995). Change in variant transthyretin levels in patients with familial amyloidotic polyneuropathy type I following liver transplantation. Biochem Biophys Res Commun 211, 354–358
   PubMed Web of Science ®Google Scholar
• Ando Y, Yamashita T, Nakamura M, Tanaka Y, Hashimoto M, Tashima K, Suhr O, Uemura Y, Obayashi K, Terazaki H, Suga M, Uchino M and Ando M (1997). Down regulation of a harmful variant protein by replacement of its normal protein. Biochem Biophys Acta 1362, 39–46
   PubMed Web of Science ®Google Scholar
• Kelly JW and Lansbury PT, Jr (1994). A chemical approach to elucidate the mechanism of transthyretin and β-protein amyloid formation. Amyloid. Int J Exp Clin Invest 1, 186–205
   Web of Science ®Google Scholar
• Colon W and Kelley JW (1992). Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8654–8660
   PubMed Web of Science ®Google Scholar
• McCutchen SL, Colon W and Kelley JW (1993). Transthyretin mutation Lcu-55-Pro alters tetrameric stability and increases amyloidogenicity. Biochemistry 32, 12119–12127
   PubMed Web of Science ®Google Scholar
• Alves IL, Divino CM, Schussler GC, Altland K, Almeida MR, Palha JA, Coelho T, Costa PP and Saraiva MJ (1993). Thyroxine binding in a TTR Met 119 kindred. J Clin Endocrinol Metab 77, 484–488
   PubMed Web of Science ®Google Scholar
• Longo Alves I, Hays MT and Saraiva MJ (1997). Comparative stability and clearance of [Met30]transthyretin and [Met119]transthyretin. Eur J Biochem 249, 662–668
   PubMedGoogle Scholar
• Almeida MR, Damas AM, Lans MC, Brouwer A and Saraiva MJ (1997). Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis. Endocrine 6, 309–315
   Google Scholar
• Almeida MR, Alves IL, Terazaki H, Ando Y and Saraiva MJ (2000). Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M. Biochem Biophys Res Commun 270, 1024–1028
   PubMed Web of Science ®Google Scholar
• Terazaki H, Ando Y, Misumi S, Nakamura M, Ando E, Matsunaga N, Shoji S, Okuyama M. Ideta H, Nakagawa K, Ishizaki T, Ando M and Saraiva MJ (1999). A novel compound heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels. Biochem Biophys Res Commun 264, 365–370
   PubMed Web of Science ®Google Scholar
• Baures PW, Oza VB, Peterson SA and Kelly JW (1999). Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg Med Chem 7, 1339–1347
   PubMed Web of Science ®Google Scholar
• Peterson SA, Klabunde T, Lashuel HA, Purkey H, Sacchettini JC and Kelly JW (1998). Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci USA 95, 12956–12960
   PubMed Web of Science ®Google Scholar
• Mikami F, Ando Y, Imasato A, Tajiri T, Sato T, Shuto T and Kai H. Transthyretin amyloidogenesis altered by Cr3+ and Al3+. Presented at the 5th International Symposium on Familial Amyloidotic Polyneuropathy and Other Transthyretin Related Disorders (Abstract). 2003
   Google Scholar
• Guy CD and Jones CK (2001). Abdominal fat pad aspiration biopsy for tissue confirmation of systemic amyloidosis: Specificity, positive predictive value, and diagnostic pitfalls. Diagn Cytopathol 24,181–185
   PubMed Web of Science ®Google Scholar
• Kaplan B, Vidal R, Kumar A, Ghiso J and Gallo G (1999). Immunochemical microanalysis of amyloid proteins in fine-needle aspirates of abdominal fat. Am J Clin Pathol 112, 403–407
   PubMed Web of Science ®Google Scholar
• Masouye I (1997). Diagnostic screening of systemic amyloidosis by abdominal fat aspiration: An analysis of 100 cases. Am J Dermatopathol 19, 41–45
   PubMed Web of Science ®Google Scholar
• Westermark GT and Westermark P (2000). Endocrine amyloid a subject of increasing interest for the next century. Amyloid: Int J Exp Clin Invest 7, 19–22
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lavender JP and Pepys MB (1990). Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 323, 508–513
   PubMed Web of Science ®Google Scholar
• Puille M, Altland K, Linke RP, Stecn-Muller MK, Klett R, Steiner D and Bauer R (2002). 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur J Nucl Med 29, 376–379
   Google Scholar
• Giger M, Baumgartner HR and Zbinden G (1974). Toxicological effects of Evans blue and Congo red on blood platelets. Agents Actions 4,173–180
   PubMedGoogle Scholar
• Klunk WE, Debnath ML and Pettegrew JW (1995). Chrysamine-G binding to Alzheimer and control brain: Autopsy study of a new amyloid probe. Neurobiol Aging 16, 541–548
   PubMed Web of Science ®Google Scholar
• Klunk WE, Debnath ML, Koros AM and Pettegrew JW (1998). Chrysamine-G, a lipophilic analogue of Congo red, inhibits A beta-induced toxicity in PC 12 cells. Life Sci 63, 1807–1814
   PubMed Web of Science ®Google Scholar
• Dezutter NA, Sciot RM, de Groot TJ, Bormans GM and Verbruggen AM (2001). In vitro affinity of 99Tcm-labelled N2S2 conjugates of chrysamine G for amyloid deposits of systemic amyloidosis. Nucl Med Commun 22, 553–558
   PubMed Web of Science ®Google Scholar
• Dezutter NA, Landman WJ, Jager PL, de Groot TJ, Dupont PJ, Tooten PC, Zekarias B, Gruys E and Verbruggen AM (2001). Evaluation of 99mTc-MAMA-chrysamine G as an in vivo probe for amyloidosis. Amyloid: Int J Exp Clin Invest 8, 202–214
   PubMed Web of Science ®Google Scholar
• Dezutter NA, Dom RJ, de Groot TJ, Bormans GM and Verbruggen AM (1999). 99mTc-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer's disease. Eur J Nucl Med 26, 1392–1399
   PubMedGoogle Scholar
• Skovronsky DM, Zhang B, Kung MP, Kung HF, Trojanowski JQ and Lee VM (2000). In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 97, 7609–7614
   PubMed Web of Science ®Google Scholar
• Schmidt ML, Schuck T, Sheridan S, Kung MP, Kung H, Zhuang ZP, Bergeron C, Lamarche JS, Skovronsky D, Giasson BI, Lee VM and Trojanowski JQ (2001). The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy) styrylbenzene (BSB), labels diverse beta-pleated sheet structures in postmortem human neurodegenerative disease brains. Am J Pathol 159, 937–943
   PubMed Web of Science ®Google Scholar
• Klunk WE, Debnath ML and Pettegrew JW (1994). Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging 15, 691–698
   PubMed Web of Science ®Google Scholar
• Zhuang ZP, Kung MP, Hou C, Plossl K, Skovronsky D, Gur TL, Trojanowski JQ. Lee VM and Kung HF (2001). IBOX(2-(4'-dimethylaminophenyl)-6-iodobenzoxazolc): A ligand for imaging amyloid plaques in the brain. Nucl Med Biol 28, 887–894
   PubMed Web of Science ®Google Scholar
• Okahata Y, Niikura K, Sugiura Y, Sawada M and Morii T (1998). Kinetic studies of sequence-specific binding of GCN4-bZIP peptides to DNA strands immobilized on a 27-MHz quartz-crystal microbalance. Biochemistry 37, 5666–5672
   PubMed Web of Science ®Google Scholar
• Matsuno H, Niikura K and Okahata Y (2001). Direct monitoring kinetic studies of DNA polymerase reactions on a DNA-immobilized quartz-crystal microbalance. Chemistry 7, 3305–3312
   PubMed Web of Science ®Google Scholar
• Merlini G, Ascari E, Amboldi N, Bellotti V, Arbustini E, Perfetti V, Ferrari M, Zorzoli I, Marinone MG, Garini P, Diegori M, Trizio D and Ballinari D (1995). Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis. Proc Natl Acad Sci USA 92, 2959–2963
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzicri A, Cheson BD, Barlogie B, Kyle RA, Palladini G, Geyer SM and Merlini G (2002). A multicenter phase II trial of 4'-iodo-4'-deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid: J Protein Folding Disord 9, 24–30
   PubMed Web of Science ®Google Scholar
• Sebastiao MP, Merlini G, Saraiva MJ and Damas AM (2000). The molecular interaction of 4'-iodo-4'-deoxydox-orubicin with Leu-55Pro transthyretin ‘amyloid-like’ oligomer leading to disaggregation. Biochem J 351, 273–279
   PubMed Web of Science ®Google Scholar
• McCord JM (1980). Oxygen free radicals: Release and activities. Agents Actions 10, 522–527
   PubMedGoogle Scholar
• Hirota M, Inoue M, Ando Y, Hirayama K, Mirano Y, Sakamoto K, Mori K and Akagi M (1989). Inhibition of stress induced gastric injury in the rat by glutathione. Gastroenterology 97, 853–859
   PubMed Web of Science ®Google Scholar
• Ando E, Ando Y, Kamata R, Inoue M, Morino Y and Okamura R (1990). Inhibition of corneal inflammation by an acylated superoxide dismutase derivation. Invest Ophthalmol Vis Sci 31, 1963–1967
   PubMed Web of Science ®Google Scholar
• Ando Y, Ikegawa S, Miyazaki A, Inoue M, Morino Y and Araki S (1989). Role of variant prealbumin in the pathogenesis of familial amyloidotic polyneuropathy: Rate of normal and variant prealbumin in circulation. Arch Biochem Biophys 274, 87–92
   PubMed Web of Science ®Google Scholar
• Granger D (1988). Role of xanthine oxidase and granulocytes in ischemia-reperfusion injury. Am J Physiol 255, H1269-H1275
   PubMed Web of Science ®Google Scholar
• The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group (1994). The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330, 1029–1035
   PubMed Web of Science ®Google Scholar
• Banwell BL and Engel AC. (2000). AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 54, 1033–1041
   PubMed Web of Science ®Google Scholar
• Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I and Rydel RE (1992). β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to exeitotoxicity. J Neurosci 12, 376–389
   PubMed Web of Science ®Google Scholar
• Capeillere-Blandin C, Delaveau Tand Descamps-Latscha B (1991). Structural modifications of human beta 2 microglobulin treated with oxygen-derived radicals. Biochem J 277, 175–182
   PubMed Web of Science ®Google Scholar
• Toyokuni S, Uchida K, Okamoto K, Hattori-Nakakuki Y, Hiai H and Stadtman ER (1994). Formation of 4-hydroxy-2-nonenal-modified proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. Proc Natl Acad Sci USA 91, 2616–2620
   PubMed Web of Science ®Google Scholar
• Mark RJ, Lovell MA, Markesbery WR, Uchida K and Mattson MP (1997). A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide. J Neurochem 68, 255–264
   PubMed Web of Science ®Google Scholar
• Sagara Y, Dargusch R, Klier FG, Schubert D and Behl C (1996). Increased antioxidant enzyme activity in amyloid β protein-resistant cells. J Neurosci 16, 497–505
   PubMed Web of Science ®Google Scholar
• Skinner M, Stone P, Shirahama T, Connors L, Calore J and Cohen A (1986). The association of an elastase with amyloid fibrils. Proc Soc Exp Biol Med 181, 211–214
   PubMed Web of Science ®Google Scholar
• Stone P, Camistol J, Abraham CR, Rodgers O. Shirahama T and Skinner M (1993). Neutrophil proteases associated with amyloid fibrils. Biochem Biophys Res Commun 30, 130–136
   Web of Science ®Google Scholar
• Benedetti A, Comporti M and Esterbauer H (1980). Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. Biochim Biophys Acta 620, 281–296
   PubMed Web of Science ®Google Scholar
• Siems W, Kowalewski J, Werner A, Schimke I and Gerber G (1989). Radical formation in the rat small intestine during and following ischemia. Free Radic Res Commun 7, 347–353
   PubMed Web of Science ®Google Scholar
• Uchida K, Itakura K, Kawakishi S, Hiai H, Toyokuni S and Stadtman ER (1995). Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies. Arch Biochem Biophys 324, 241–248
   PubMed Web of Science ®Google Scholar
• Ando Y, Br nnstr m T, Uchida K, Nyhlin N, N sman B, Suhr O, Yamashita T, Olsson T, Uchino M and Ando M (1998). Histochemical detection of 4-hydroxynonenal protein in Alzheimer disease amyloid. J Neurol Sci 156, 172–176
   PubMed Web of Science ®Google Scholar
• Hoff HF and O Neil JA (1991). Oxidation of LDL: Role in atherogenesis. Klin Wochenschr 69, 1032–1038
   PubMedGoogle Scholar
• Sakashita N, Ando Y, Jinnouchi K, Yoshimatsu M. Terazaki H, Obayashi K and Takeya M (2001). Familial amyloidotic polyneuropathy (ATTR Val30Met) with widespread cerebral amyloid angiopathy and lethal cerebral hemorrhage. Pathol Int 51, 476–480
   PubMed Web of Science ®Google Scholar
• Ando Y, Nyhlin N, Suhr O, Holmgren G, Uchida K, El-Salhy M, Yamashita T, Terasaki H, Nakamura M, Uchino M and Ando M (1997). Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem Biophys Res Commun 232, 497–502
   PubMed Web of Science ®Google Scholar
• Ando Y, Suhr O and El-Salhy M (1998). Oxidative stress and amyloidosis. Histol Histopathol 13, 845–850
   PubMed Web of Science ®Google Scholar
• Nyhlin N, Ando Y, Nagai R, Suhr O, El-Salhy M, Terazaki H, Yamashita, Ando M and Horiuchi S (2000). Advanced glycation end product in familial amyloidotic polyneuropathy (FAP). J Intern Med 247, 485–492
   PubMed Web of Science ®Google Scholar
• Sakashita N, Ando Y, Marklund SL, Tashima K, Nilsson P, Yamashita T, Takeya M and Takahashi K (1998). Familial amyloidotic polyneuropathy type I with extracellular superoxide dismutase mutation: A case report. Hum Pathol 13, 845–850
   Google Scholar
• Suhr OB, Lang K, Wikstrom L, Anan I, Ando Y, El-Salhy M, Holmgren G and Tashima K (2001). Scavenger treatment of free radical injury in familial amyloidotic polyneuropathy: A study on Swedish transplanted and non-transplanted patients. Scand J Clin Lab Invest 61, 11–18
   PubMed Web of Science ®Google Scholar
• Propsting MJ, Blaschke M, Haas RE, Genschel J, Hedrich HJ, Manns MP and Schmidt HH (1999). Inosine(15.1)-hammerhead ribozymes for targeting the transthyretin-30 mutation. Biochem Biophys Res Commun 260, 313–317
   PubMed Web of Science ®Google Scholar
• Tanaka K, Yamada T, Ohyagi Y. Asahara H, Horiuchi I and Kira J (2001). Suppression of transthyretin expression by ribozymes: A possible therapy for familial amyloidotic polyneuropathy. J Neurol Sci 183, 79–84
   PubMed Web of Science ®Google Scholar
• Yoon K, Cole-Strauss A and Kmiec EB (1996). Targeted gene correction of episomal DNA in mammalian cells mediated by a chimeric RNA.DNA oligonucleotide. Proc Natl Acad Sci USA 93, 2071–2076
   PubMed Web of Science ®Google Scholar
• Cole-Strauss A, Yoon K, Xiang Y, Byrne BC, Rice MC, Gryn J, Holloman WK and Kmiec EB (1996). Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science 273, 1386–1389
   PubMed Web of Science ®Google Scholar
• Kren BT, Cole-Strauss A, Kmiec EB and Steer CJ (1997). Targeted nucleotide exchange in the alkaline phosphatase gene of HuH-7 cells mediated by a chimeric RNA/DNA oligonucleotide. Hepatology 25, 1462–1468
   PubMed Web of Science ®Google Scholar
• Xiang Y, Cole-Strauss A, Yoon K, Gryn J and Kmiec EB (1997). Targeted gene conversion in a mammalian CD34+-enriched cell population using a chimeric RNA/DNA oligonucleotide. J Mol Med 75, 829–835
   PubMed Web of Science ®Google Scholar
• Kren BT, Bandyopadhyay P and Steer CJ (1998). In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotide. Nat Med 4, 285–290
   PubMed Web of Science ®Google Scholar
• Alexeev V and Yoon K (1998). Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA/DNA oligonucleotide. Nat Biotechnol 16, 1343–1346
   PubMed Web of Science ®Google Scholar
• Kren BT, Parashar B, Bandyopadhyay P, Chowdhury N, Chowdhury JR and Steer CJ (1999). Correction of the UDP-glucuronosyltransferase gene defect in the Gunn rat model of Crigler-Najjar syndrome type I with a chimeric oligonucleotide. Proc Natl Acad Sci USA 96, 10349–10354
   PubMed Web of Science ®Google Scholar
• Gamper HB Jr, Cole-Strauss A, Metz R, Parekh H, Kumar R and Kmiec EB (2000). A plausible mechanism for gene correction by chimeric oligonucleotides. Biochemistry 39, 5808–5816
   PubMed Web of Science ®Google Scholar
• Gamper HB, Parekh H, Rice MC, Bruner M, Youkey H and Kmiec EB (2000). The DNA strand of chimeric RNA/DNA oligonucleotides can direct gene repair/conversion activity in mammalian and plant cell-free extracts. Nucleic Acids Res 28, 4332–4339
   PubMed Web of Science ®Google Scholar
• Kishikawa M, Nakanishi T, Miyazaki A and Shimizu A. (1999). Enhanced amyloidogenicity of sulfonated transthyretin in vitro, a hypothetical etiology of senile amyloidosis. Amyloid: hit J Exp Clin Invest 6, 183–186
   PubMed Web of Science ®Google Scholar
• Altland K and Winter P (1999). Potential treatment of transthyretin-type amyloidoses by sulfite. Neurogenetics 2, 183–188
   PubMed Web of Science ®Google Scholar
• Cardoso I, Pereira PJ, Damas AM and Saraiva MJ (2000). Aprotinin binding to amyloid fibrils. Eur J Biochem 267, 2307–2311
   PubMedGoogle Scholar
• Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K. Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M and Arendash GW (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982–985
   PubMed Web of Science ®Google Scholar
• Imbimbo BP (2002). Toxicity of beta-amyloid vaccination in patients with Alzheimer's disease. Ann Neurol 51, 794
   PubMed Web of Science ®Google Scholar